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Abstract
Background: Increasing studies have shown that dyslipidemia and inflammatory responses play important roles in the
progression of microvascular diabetic complications. Esculin (ES), a coumarin derivative, was extracted from Fraxinus
rhynchophylla. The present study was to evaluate the potential effects of ES on lipid metabolism, inflammation responses
and renal damage in streptozotocin (STZ)-induced experimental diabetic rats and explore the possible mechanism.
Methods: Diabetic rat model was established by administration high-glucose-fat diet and intraperitoneal injection of STZ
45 mg/kg. ES was administrated to diabetic rats intragastrically at 10, 30 and 90 mg/kg for 10 weeks respectively. The
levels of triglycerides (TG), total cholesterol (T-CHO), low density lipoproteins (LDL), and high-density-cholesterol (HDL-C)
in serum were measured. IL-1, IL-6, ICAM-1, NO, NAGL, and AGEs level in serum were detected by ELISA assay. The
accumulation of AGEs in kidney tissue was examined by immunohistochemistry assay.
Results: The results showed that ES could decrease TG, T-CHO, LDL levels in serum of diabetic rats in a dose
dependent manner. ES also decreased IL-1, IL-6, ICAM-1, NO and NGAL levels in serum of diabetic rats in a dose
dependent manner. Furthermore, ES at 30 and 90 mg/kg significantly decreased AGEs level in serum and alleviated
AGEs accumulation in renal in diabetic rats.
Conclusions: Our findings indicate that ES could improve dyslipidemia, inflammation responses, renal damage in
STZ-induced diabetic rats and the possible mechanism might be associated with the inhibition of AGEs formation.
Keywords: Esculin, Diabetic complications, Dyslipidemia, Advanced glycation end products (AGEs)
Background
Diabetes mellitus is characterized by hyperglycaemia,
hypercholesterolemia and hypertriglyceridemia, resulting
from defects in insulin secretion followed by dysfunction
and failure of organs especially the eyes, kidneys, nerves,
heart and arteries [1]. Abnormalities in lipid profile are
one of the most common complications in diabetes mel-
litus [2]. The key components of diabetic dyslipidemia
are elevated plasma low density lipoproteins (LDL), tri-
glycerides (TGs), and lowered high density lipoprotein
(HDL-C) [3]. Several studies have also demonstrated
that inflammatory processes play a crucial role in the de-
velopment of diabetic complications. In the present
study, in order to verify the effects of ES on anti-diabetic
complications, we investigated the level of proinflamma-
tory cytokines in the diabetic rats.
Diabetic nephropathy is a major microvascular com-
plication of diabetes mellitus and the most common
cause of renal failure. The renal injury in diabetic ne-
phropathy is due to a series of complex pathophysio-
logical changes such as glomerulosclerosis, vascular
diseases and changes of the tubulointerstitium with tubu-
lar atrophy and interstitial fibrosis initiated by disturbed
glucose homeostasis [4]. Neutrophil gelatinase-associated
lipocalin (NGAL), a 25 kDa protein belonging to the lipo-
calin superfamily, was initially found in activated neutro-
phils. However, many other cells, like kidney tubular cells,
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may also produce NGAL in response to various insults
[5]. Both serum and uric NGAL have been found to be re-
liable predictors of kidney injury [6].
Recent studies have suggested that advanced glycation
end products (AGEs) are believed to play a crucial role
in the pathogenesis of diabetic complications [7]. AGEs
ligate to the receptor of AGEs (RAGE), facilitating acti-
vation of the transcription factor NFκB may be involved
in the development of diabetic complications [8].
Esculin (Fig. 1), a coumarin derivative, was extracted
from Fraxinus rhynchophylla, belonging to the Oleaceae
family, which is widely distributed in the east of Asia, es-
pecially in the south of China. In diabetes-related stud-
ies, it has been demonstrated that esculin and its
metabolite esculetin inhibit formation of advanced glyca-
tion end-products formation [9], inhibit the activities of
α-glucosidase and protein tyrosine phosphatase 1B [10],
and have the beneficial effect against diabetes and oxida-
tive stress-related inflammatory processes in the kidney
of mice [11]. However, studies on the effect and mech-
anism of esculin on diabetic rats are limited. Therefore,
we investigated the effect and possible mechanism of
esculin against dyslipidemia, inflammation responses




Esculin was purchased from Nanjing Zelang Medical
Technology Co., Ltd (Nanjing, China). Streptozotocin was
purchased from Sigma-Aldrich Co. (St. Louis, MO, USA).
Triglyceride, total cholesterol, LDL cholesterol and HDL
cholesterol were assayed using kits from Applygen
Coporation (Beijing, China). One touch gluco-meter
(Accu-chek sensor) was Roche products. IL-1 and IL-6
ELISA kits were purchased from ExCell Bio (Genetimes
Technology, Inc., Beijing, China), ICAM-1 and NAGL
ELISA Kits were purchase from Wuhan Boster Bio-
engineering limited company (Wuhan, China). NO level
was assayed by Griess Regant System from Promega
Corporation (Madison, USA). AGEs ELISA Kit was pur-
chase from CELL BIOLABS INC. (San Diego, CA). High-
sugar-fat chow was added 10 % sugar, 10 % lard, 2 % chol-
esterol, 0.2 % cholic acid in the standard of rat chow.
Animals
Adult male Sprague–Dawley rats (200–220 g) were pur-
chased from the Animal Centre of Beijing Vitra Liver
(Beijing, China). All animals were housed in a room with
controlled temperature of 23 ± 2 °C and humidity of 55 ±
5 % with a regular 12 h light–dark cycle and allowed to
have water and food ad libitum. All animal care and ex-
perimental procedures regarding the animals were ap-
proved by the ethic committees of Institute of Materia
Medica, Chinese Academy of Medical Sciences & Peking
Union Medical College.
STZ-induced experimental diabetic rats and experimental
design
Diabetes was induced in all the rats except a group of
ten animals which were treated as normal control group
by intraperitoneal administration of STZ (45 mg/kg) dis-
solved in freshly prepared citrate buffer (pH 4.5). The
animals were fasted for 12 h before STZ administration
and blood glucose was estimated after 72 hours of STZ
administration. The animals with blood glucose more
than 16.7 mmol/l were treated as diabetic and the ani-
mals were divided into 6 groups (n = 10): one group was
served as diabetic control; ES-L, ES-M, and ES-H groups
were received esculin 10 mg/kg, 30 mg/kg and 90 mg/kg
by per oral administration respectively for a period of 10
weeks; AG group was served as positive group by per
oral administration. After administration, rats were anes-
thetized and killed, serum was collected. The kidney was
separated and fixed in 4 % polyformaldehyde for histo-
pathology assay and immunochemistry staining.
Determination of lipid profile in serum
Triglyceride (TG), Total cholesterol (TC), low density
lipoprotein (LDL), high density lipoprotein (HDL) con-
tent in serum were assayed following the manufacturer’s
protocol.
Determination of IL-1, IL-6, ICAM-1, NO, AGEs, and NAGL
level in serum
IL-1, IL-6, ICAM-1, NO, AGEs, and NAGL level in
serum were measured according to the manufacturer’s
protocol.
Histological examination
After fixation, renal tissues were stained with
hematoxylin and eosin (HE) reagents for histological
examination and examined under the microscope.
Fig. 1 The chemical structure of esculin
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AGEs level estimated in renal by immunochemistry
AGEs levels in renal were determined by immunochem-
istry staining on 4 % polyformalin-fixed paraffin sections
(2-μm-thick). Briefly, the deparaffinized and rehydrated
tissue sections were incubated with 3 % hydrogen perox-
ide to block endogenous peroxidase and then subjected
to antigen retrieval through microwave oven heating in
0.1 M sodium citrate (pH 6.0) for 10 min. After that, tis-
sue sections were incubated with 10 % normal goat
serum for 10 min followed by an overnight incubation
with anti-AGEs (1:100) antibody in 10 % normal goat
serum at 4 °C. The sections were washed, further incu-
bated with horseradish peroxidase (HRP)-labeled goat
anti-rabbit/mouse polyclonal antibody for 20 min at 37 °C,
and developed with 3,3-diaminobenzidine (DAB, Sigma)
for color reaction. The sections were then counterstained
with hematoxylin. All measurements were performed
blindly.
Statistical analysis
All data are expressed as the mean ± SD. Statistical ana-
lysis of the results was carried out by one-way analysis
of variance (ANOVA), followed by t-test. Statistical sig-
nificance was accepted at P < 0.05.
Results
Effect of ES on body weight and blood glucose in
STZ-induced diabetic rats
The diabetic model rats exhibited reduced body weight
and increased blood glucose levels compared with nor-
mal control rats (both P < 0.01). However, there were no
effect on body weight (Fig. 2a) and blood glucose
(Fig. 2b) observed in ES or AG-treated rats.
Effect of ES on biochemical parameters in STZ-induced
diabetic rats
In diabetic control rats, TG, T-CHO, and LDL levels
were all significantly increased when compared to nor-
mal rats (all P < 0.01). However, treatment with ES
dose-dependently attenuated the increase in TG, T-CHO,
and LDL from the diabetic rats (Fig. 3a, b, and c), but
these levels were still higher than that observed in normal
rats and AG-treated rats. These findings indicate that ES
is able to ameliorate diabetes signs to a certain extent.
Rats in the diabetic model group demonstrated signifi-
cant decrease of HDL compared to the control group
(P < 0.01). However, after treatment with ES, there was
no significant change in HDL level all of these parame-
ters improved significantly. Similar significant improve-
ments in these parameters occurred in the AG group as
well (Fig. 3d).
Effect of ES on inflammatory factors in STZ-induced
diabetic rats
In diabetic model rats, IL-1, IL-6, ICAM-1 and NO
levels were all significantly increased compared with nor-
mal control rats (P < 0.05, P < 0.05, P < 0.01, P < 0.01,
respectively). However, treatment with ES dose-
dependently attenuated the increase in IL-1, IL-6, ICAM-
1 and NO levels from the diabetic rats (Fig. 4). These
findings indicate that ES is able to ameliorate inflam-
matory responses to a certain extent in diabetic rats.
Effect of ES on NAGL level in serum in STZ-induced
diabetic rats
As shown in Fig. 5, the NAGL level in serum was signifi-
cantly increased in STZ-induced diabetic rats compared
with the normal control rats (P < 0.01). However, treat-
ment with ES 30 and 90 mg/kg significantly decreased
the NAGL levels compared with the diabetic model
group (both P < 0.05), and the level was lower than that
observed in AG-treated rats (Fig. 5). These results indi-
cate that to some extent, ES is able to protect against
diabetic kidney injury.
Fig. 2 Effects of ES on body weight and blood sugar in STZ-induced
diabetic rats. a Body weight; b Blood sugar. Data are expressed as
means ± S.D. (n = 6 ~ 8). ## P < 0.01 vs normal control group; *P < 0.05,
**P < 0.01 vs diabetic model group
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Effect of ES on AGEs level in serum in STZ-induced
diabetic rats
As shown in Fig. 6, the AGEs level in serum was signifi-
cantly increased in STZ-induced diabetic rats compared
with the normal control rats (P < 0.01). In contrast,
treatment with ES 30 and 90 mg/kg significantly de-
creased the AGEs levels compared with the diabetic
model group (P < 0.05, P < 0.01, respectively). These re-
sults indicate that to some extent, ES is able to protect
against AGEs level increase in diabetic rats.
Effect of ES against STZ-induced diabetic renal
histopathological changes in rats
HE staining was performed on renal sections to measure
tubular damage. As shown in the representative pictures
of renal sections, severe tubulointerstitial injuries includ-
ing tubular epithelial cell detachments, cystic dilatation
of tubules, and inflammatory cell infiltration occurred in
kidneys of STZ-treated diabetic rats. However, the
increased tubular damage in STZ-treated mice was re-
duced by treatment with esculin (Fig. 7).
Effect of ES against STZ-induced AGEs accumulation in
renal of rats
Accumulation of AGEs is observed in kidney of diabetic
rats, for which these molecules contribute to diabetes
complications. In the present study, an increase of AGEs
accumulation was found in the renal of the diabetic
model group; however, treatment with ES 30 and 90 mg/kg
resulted in obviously reduced AGEs accumulation (Fig. 8).
These results indicate that ES is able to inhibit the nonen-
zymatic glycation of protein in vivo and may help to attenu-
ate renal injury in diabetic rats.
Discussion
Diabetes is increasing at epidemic proportions throughout
the world. Most of the morbidity and mortality associated
with diabetes results from macro and microvascular
Fig. 3 Effect of ES on TG, T-CHO, LDL, and HDL levels in STZ-induced diabetic rats. a TG level; b T-CHO level; c LDL level; d HDL level. Data are
expressed as means ± S.D (n = 6 ~ 8). Data are expressed as means ± S.D. (n = 6 ~ 8). ##P < 0.01 vs normal control group; *P < 0.05, **P < 0.01 vs
diabetic model group
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Fig. 4 Effect of ES on inflammation responses in STZ-induced diabetic rats. a IL-1 level; b IL-6 level; c ICAM-1 level; d NO level. Data are expressed as
means ± S.D. (n = 6 ~ 8). Data are expressed as means ± S.D. (n = 6 ~ 8). ##P < 0.01 vs control group; *P < 0.05, **P < 0.01 vs diabetic model group
Fig. 5 Effect of ES on NAGL level in STZ-induced diabetic rats. Data are
expressed as means ± S.D. (n = 6 ~ 8). Data are expressed as means ±
S.D. (n = 6 ~ 8). ## P < 0.01 vs control group; *P < 0.05, **P < 0.01 vs
diabetic model group
Fig. 6 Effect of ES on AGEs level in STZ-induced diabetic rats. Data
are expressed as means ± S.D. (n = 6 ~ 8). Data are expressed as
means ± S.D. (n = 6 ~ 8). ## P < 0.01 vs control group; *P < 0.05,
**P < 0.01 vs diabetic model group
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complications [12, 13]. Compared to macrovascular com-
plications, microvascular complications, such as retinop-
athy, neuropathy, nephropathy, are much earlier and
common in diabetes. Approximately 40 % of patients with
diabetes may progress to nephropathy and a good meta-
bolic control can prevent the development of diabetic
renal injury [14]. Hyperglycaemia and dyslipidemia are
two pathological characteristics of diabetes [15, 16]. In-
creased levels of glucose and lipids in serum and kidney
can directly stimulate oxidative stress, inflammation, fibro-
sis and advanced glycation end products (AGEs) products
formation in tubular and glomerular structures [17, 18].
Esculin, a coumarin derivative, was extracted from
Fraxinus rhynchophylla, which belonging to a traditional
medicinal plant from East Asia. Thuong PT, et al. [19]
found that derivative coumarins fraxetin has direct pro-
tective properties against LDL oxidation at lower
concentrations, and higher concentrations of fraxetin in-
duce antioxidant enzymes via Nrf2/ARE activation.
These effects suggest potential anti-atherosclerosis ef-
fects of Fraxinus rhynchophylla. Naaz F, et al. [20] dem-
onstrated that the protective efficacy of esculin against
pro-oxidant AFB1-induced nephrotoxicity in mice might
be due to its antioxidants and free radical scavenging
properties. Kang KS, et al. [11] found that esculin less-
ened the elevated blood creatinine levels in diabetic mice
and ameliorated diabetes-induced renal dysfunction by
reducing caspase-3 activation in the kidney. However,
our results showed that ES could improve dyslipidemia,
inflammation responses, renal damage in STZ-induced
diabetic rats and the possible mechanism might be asso-
ciated with the inhibition of AGEs formation. In this
study, the results also showed that hyperglycaemia, dys-
lipidemia and systemic inflammatory responses were
Fig. 7 Effects of esculin on renal histopathological changes in the STZ-induced diabetes rats by HE staining. Representative photomicrographs of
the renal in different groups. Magnification: ×200
Fig. 8 Effect of ES on renal AGEs accumulation in STZ-induced diabetic rats by immunochemistry. Representative photomicrographs of the renal
in different groups. Magnification: ×200
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observed in STZ-induced diabetes rats. However, ES sig-
nificantly improved dyslipidemia in diabetes, but did not
significantly change the level of blood glucose.
Previous reports suggested that several humoral
markers of inflammation are elevated in diabetic patients
and inflammation is involved in the progression of dia-
betic nephropathy. Some pro-inflammatory cytokines,
such as IL-6, IL-1β, and TNF-α are involved in matrix
expansion and mesangial cells proliferation leading to
glomerular fibrosis [21]. In the present study, our results
showed that ES could dose-dependently attenuate the
increase of IL-1, IL-6, ICAM-1 and NO levels in STZ-
induced diabetic rats. These findings indicate that ES is
able to ameliorate inflammation responses to a certain
extent in diabetic rats.
Diabetic nephropathy is associated with mesangial cell
expansion, thickening of glomerulra and tubular base-
ment membrane, glomerulosclerosis and tubular necro-
sis. Previous reports suggested that the presence of
hyperglycaemia and dyslipidemia causes functional and
morphological kidney alterations that can induce renal
dysfunction [15, 16]. Dyslipidemia can induce a glom-
erular phenotype characterized by proliferative and pro-
inflammatory response, monocyte infiltration, increased
extracellular matrix and podocytes degeneration [18]. It
has been demonstrated that diabetes-induced oxidative
stress and lipid alteration, in addition to a marked glu-
cose elevation, play a detrimental role in the onset of ne-
phropathy in diabetic animals [22, 23]. In the present
study, it was shown that ES could obviously improve
renal damage in STZ-induced diabetes rats.
Due to prolonged high glucose in diabetes, reducing
sugars can react non-enzymatically with the amino
groups to initiate a complex series of rearrangements
and dehydrations, and then to produce a class of irre-
versibly cross-linked moieties termed AGEs [24]. The ac-
cumulation of AGEs is an important feature in the
development of diabetic complications [25, 26]. The for-
mation and accumulation of AGEs in various tissues
have been shown to progress at an accelerated rate
under hyperglycemic conditions [27, 28]. There is accu-
mulating evidence that AGEs and receptor for AGEs
interaction induces oxidative stress generation and sub-
sequently evokes inflammatory reactions, thereby caus-
ing progressive alteration in renal architecture and loss
of renal function in diabetes [29–31]. In particular, AGEs
are thought to be involved in the pathogenesis of dia-
betic nephropathy via multifactorial mechanisms such as
oxidative stress generation and overproduction of vari-
ous growth factors and cytokines [32]. It is reported that
AGEs have been recently shown to increase leukocyte
adhesion to cultured retinal microvascular endothelial
cells by inducing intracellular cell adhesion molecule-1
(ICAM-1) expression [33].AGEs modification of proteins
may produce in changes charge, solubility, and conform-
ation leading to molecular dysfunction as well as dis-
rupting interactions with other proteins. AGEs also
interact with specific receptors and binding proteins to
influence the renal expression of growth factors and cy-
tokines, implicated in the progression of diabetic renal
disease [34].
Investigations by others also demonstrated that forma-
tion of AGEs is an important pathophysiological mech-
anism in the development of diabetic nephropathy [35].
Jung HA, et al. have found that esculin may play a cru-
cial role in AGE inhibition and may be as potential can-
didates for use as therapeutic or preventive agents for
diabetic complications [9]. In agreement with this, our
research firstly demonstrated the inhibitory effect of ES
on AGE formation in diabetic rats. The results showed
that in serum of normal rats, the level of AGEs was very
low, but in diabetic rats, it was significantly increased.
However, the increase of AGEs level in serum was obvi-
ously depressed by the administration of ES and AG. In
this present study, we also found that the accumulation
of AGEs in renal, especially in glomerulra, was increased
in STZ-induced diabetic rats, which was correlated with
renal damage. Moreover, ES administration reduced the
accumulation of AGEs in diabetic rats. These observa-
tions suggested that ES could restrain the AGEs accu-
mulation in kidney. Therefore, these results suggest that
AGEs accumulation might play a considerable role in
the diabetic nephropathy and it is likely that inhibiting
the formation of AGEs or removing established AGEs
modifications will form an important component part of
future therapy in patients with diabetes, acting in con-
cert with conventional approaches to prevent diabetic
renal injury.
Conclusions
In conclusion, our research confirmed that ES had a
protective effect against lipid metabolism disorders, in-
flammation responses, and renal injury in diabetic rats,
the mechanism of which may be at least partly corre-
lated with the amelioration of AGEs accumulation.
Therefore, it can be concluded that ES may help to
attenuate diabetes nephropathy.
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